Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030

Internal and Emergency Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Abstract The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing globally, posing a major public health issue. This study analyzes the global, regional, and national burden MASLD its risk factors from 1990 to 2021, with projections 2030. We obtained data on prevalence, deaths, disability-adjusted life years (DALYs) Global Burden Disease 2021 for 204 countries. Counts rates per 100,000 population were calculated, trends 2030 predicted using Bayesian Age-Period-Cohort model. In there 1,267.9 million cases 138.3 thousand deaths 3667.3 DALYs. global age-standardized death, DALY 15,018.1, 1.6, 42.4 population, by 24.3%, 5.5%, 5.5% since 1990. North Africa Middle East had highest while Andean Central Latin America death rates. Men aged 15–69 90–94 higher rates, women 70–89 95+ A reversed V-shaped association was found between sociodemographic index rate. High fasting plasma glucose (5.9%) smoking (2.4%) factors. Public efforts should prioritize early detection management in younger populations develop targeted strategies older adults, especially women, reduce burden. Effective policies address high can mitigate MASLD’s impact.

Language: Английский

---

Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-Analysis

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(3), P. 281 - 281

Published: March 2, 2024

Healthcare visits were reduced during the COVID-19 pandemic, causing disturbances in sustainable MAFLD monitoring. Telemedicine acts to maintain connectivity between patients and healthcare professionals. This review aimed assess role of telemedicine monitoring pandemic. Databases searched included l PubMed Central ScienceDirect from 2020 2023. Assessment with The Cochrane Risk Bias for randomized controlled trials (RCTs) Newcastle-Ottawa scale non-RCTs systematic reviews. Meta-analyses employing a random-effect model performed determine pooled mean difference (MD) p-value. results showed three RCT two non-RCT (n = 239) 56.9% males age 51.3 years. median intervention duration was 5.5 months. parameters assessed body weight (BW), mass index (BMI), waist circumference, liver function (AST/ALT), lipid profile, HbA1c, others. Meta-analysis revealed that had significant effect on improving outcomes BW (MD −2.81: 95% CI, −4.11, −1.51, p < 0.0001) BMI −1.01: −1.47, −0.55, compared standard care, while AST/ALT levels not significantly reduced. Some biochemical markers decreased based In conclusion, using mobile-based applications could be an option lifestyle modification facing

Language: Английский

---

Health in All Policies: Working Across Sectors in Cooperative Extension to Promote Health for All

Journal of Human Sciences and Extension, Journal Year: 2018, Volume and Issue: unknown

Published: May 14, 2018

A Health in All Policies approach engages cross-sector stakeholders to collaboratively improve systems that drive population health. We, the members of Extension Committee on Organization and Policy (ECOP)’s Action Team, propose adopting a within national Cooperative System will better prepare us contribute meaningfully improving nation’s We first explain argue for why how it is relevant Extension. then present insights gathered from Family Consumer Sciences program leaders state specialists assess whether leadership are poised adopt their affiliated programs. Although participant saw value contributing health improvement, they generally system as having lower levels readiness such an approach. Six themes emerged ways increase Extension’s engagement Policies: paradigm shift Extension, professional development competencies, transformational support, continued new partnerships, information access all disciplines

Language: Английский

---

Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis

Medicina, Journal Year: 2023, Volume and Issue: 59(7), P. 1239 - 1239

Published: July 3, 2023

Background and Objective: The association of non-alcoholic fatty liver disease (NAFLD) metabolic-associated (MAFLD) with intensive care unit (ICU) admissions the need for mechanical ventilation severity in COVID-19 patients. Material Methods: A systematic literature review was conducted on databases: Cochrane, Embase, PubMed, ScienceDirect, Web Science from January 2019 to June 2022. Studies evaluating MAFLD using laboratory methods, non-invasive imaging, or biopsy were included. study protocol registered PROSPERO (ID CRD42022313259), PRISMA guidelines followed. NIH quality assessment tool used assessment. RevMan version 5.3 software pooled analysis. sensitivity analysis performed assess result’s stability. Results: total 37,974 patients 17 studies assessed between ICU admission. 3396 required admission: 1236 (20.41%) group 2160 (6.77%) non-MAFLD group. odds ratio 1.86 admission, p = 0.007, a (95% CI) [1.18–2.91]. 37,166 13 included invasive 1676 ventilation: 805 (14.20% all patients) 871 (2.76% patients). 2.05, 0.02, [1.12–3.74]. 5286 14 Severe seen 1623 patients, 33.17% (901/2716) 28.09% (722/2570) having severe disease. 1.59 severity, 0.010, [1.12–2.26]. Conclusions: Our meta-analysis suggests that there are significantly increased admissions, ventilation, who acquire COVID-19.

Language: Английский

---

Impact of non-alcoholic fatty liver disease on coronavirus disease 2019: A systematic review

World Journal of Hepatology, Journal Year: 2024, Volume and Issue: 16(8), P. 1185 - 1198

Published: Aug. 22, 2024

Many studies have revealed a link between non-alcoholic fatty liver disease (NAFLD) and coronavirus 2019 (COVID-19), making understanding the relationship these two conditions an absolute requirement.

Language: Английский

---